Izumi Fukuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Izumi Fukuda has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Kazue Takano
Tokyo Women’s Medical University
12 shared publications- Mototsugu Nagao
Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
10 shared publications Hitoshi Sugihara
Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
8 shared publicationsNaomi Hizuka
Tokyo Women's Medical University , Shinjuku-ku, Tokyo 162-8666
8 shared publications- Naomi Hizuka
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical College
8 shared publications Makiko Kurimoto
Tokyo Women’s Medical University
6 shared publications
Latest Publications
- 27 August 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11) , e70655
Pediatric Case of Non‐Islet Cell Tumor Hypoglycemia Driven by Hepatoblastoma: The Diagnostic Approach and Impact of Chemotherapy on Big IGF‐II
- 27 August 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11) , e70655
Pediatric Case of Non‐Islet Cell Tumor Hypoglycemia Driven by Hepatoblastoma: The Diagnostic Approach and Impact of Chemotherapy on Big IGF‐II
- Open Access
- 31 May 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (7) , bvag126
Preoperative eGFR, age, and sex predict early postoperative renal changes in acromegaly
Objective: Acromegaly induces renal alterations. However, early postoperative renal changes following rapid hormonal correction remain unclear. We assessed early postoperative changes in estimated glomerular filtration rate (eGFR) and their associated factors, focusing on preoperative eGFR, age, and sex. Methods: We retrospectively analyzed 44 patients with acromegaly who underwent trans-sphenoidal surgery between 2012 and 2024. We analyzed renal function using preoperative eGFR and changes in eGFR at postoperative day 14 (POD14) relative to preoperative values (ΔeGFR). Patients were stratified by preoperative eGFR (≥ 90 vs <90 mL/min/1.73 m2), age (<65 vs ≥65 years), and sex. Multivariate regression analyses were performed to identify factors associated with preoperative eGFR and postoperative changes. Results: The eGFR had decreased significantly by POD14, especially among patients with higher preoperative eGFR (ΔeGFR: −27, P < .0001) and in females. Significant declines in eGFR occurred in both younger and older patients, with greater reductions in younger patients. Among older patients, 3 exhibited declines in eGFR to <60 mL/min/1.73 m2 at POD14. Multivariate analysis revealed an association between female sex and greater reductions in IGF-1 standard deviation scores with larger ΔeGFR. Conclusion: To our knowledge, this is the first study to demonstrate that rapid postoperative hormonal reductions in acromegaly are associated with early eGFR declines, particularly in patients with higher baseline eGFR, females, and younger patients. While eGFR declines are modest, patients with advanced age and metabolic comorbidities may be at risk of clinically relevant renal impairment and require careful monitoring.
- 31 May 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (7) , bvag126
Open AccessPreoperative eGFR, age, and sex predict early postoperative renal changes in acromegaly
Objective: Acromegaly induces renal alterations. However, early postoperative renal changes following rapid hormonal correction remain unclear. We assessed early postoperative changes in estimated glomerular filtration rate (eGFR) and their associated factors, focusing on preoperative eGFR, age, and sex. Methods: We retrospectively analyzed 44 patients with acromegaly who underwent trans-sphenoidal surgery between 2012 and 2024. We analyzed renal function using preoperative eGFR and changes in eGFR at postoperative day 14 (POD14) relative to preoperative values (ΔeGFR). Patients were stratified by preoperative eGFR (≥ 90 vs <90 mL/min/1.73 m2), age (<65 vs ≥65 years), and sex. Multivariate regression analyses were performed to identify factors associated with preoperative eGFR and postoperative changes. Results: The eGFR had decreased significantly by POD14, especially among patients with higher preoperative eGFR (ΔeGFR: −27, P < .0001) and in females. Significant declines in eGFR occurred in both younger and older patients, with greater reductions in younger patients. Among older patients, 3 exhibited declines in eGFR to <60 mL/min/1.73 m2 at POD14. Multivariate analysis revealed an association between female sex and greater reductions in IGF-1 standard deviation scores with larger ΔeGFR. Conclusion: To our knowledge, this is the first study to demonstrate that rapid postoperative hormonal reductions in acromegaly are associated with early eGFR declines, particularly in patients with higher baseline eGFR, females, and younger patients. While eGFR declines are modest, patients with advanced age and metabolic comorbidities may be at risk of clinically relevant renal impairment and require careful monitoring.
- Open Access
- 1 April 2026
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2026 (2)
Combination therapy of pasireotide and pegvisomant for aggressive acromegaly with an immature PIT1-lineage PitNET
Summary: A 29-year-old male presented with central scotoma and was suspected of having acromegaly based on enlargement of facial features and extremities. Serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels were elevated to 10.14 ng/mL and 571 ng/mL (74.8 nmol/L, +5.73 SDS), respectively. Magnetic resonance imaging revealed a giant pituitary neuroendocrine tumor (PitNET) measuring 48 × 48 × 58 mm with bilateral cavernous sinus invasion and high T2-weighted signal intensity. Because of poor GH suppression during an acute octreotide test (100 μg subcutaneously; nadir GH 6.25 ng/mL, 19% reduction from baseline) and the invasive tumor phenotype, preoperative pasireotide (PAS) 40 mg every 4 weeks was initiated. After 2 months, partial tumor removal was performed via transsphenoidal surgery. Histological analysis revealed an immature PIT1-lineage PitNET with strong membranous expression of somatostatin receptor subtypes 2 and 5. Persistently elevated IGF-1 after surgery led to re-initiation of PAS (40 mg every 4 weeks, escalated to 60 mg), followed by the addition of pegvisomant (PEG) 10 mg/day because biochemical control could not be achieved. Combination therapy with PAS and PEG normalized IGF-1 and maintained radiological tumor stability during long-term follow-up. This case highlights that biochemical response to somatostatin receptor ligands does not necessarily correlate with receptor expression in invasive PitNETs. Pathological classification using transcription factors may help guide individualized treatment strategies. Combination therapy with PAS and PEG may represent an effective option for aggressive acromegaly caused by immature PIT1-lineage PitNETs. Learning points:
- 1 April 2026
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2026 (2)
Open AccessCombination therapy of pasireotide and pegvisomant for aggressive acromegaly with an immature PIT1-lineage PitNET
Summary: A 29-year-old male presented with central scotoma and was suspected of having acromegaly based on enlargement of facial features and extremities. Serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels were elevated to 10.14 ng/mL and 571 ng/mL (74.8 nmol/L, +5.73 SDS), respectively. Magnetic resonance imaging revealed a giant pituitary neuroendocrine tumor (PitNET) measuring 48 × 48 × 58 mm with bilateral cavernous sinus invasion and high T2-weighted signal intensity. Because of poor GH suppression during an acute octreotide test (100 μg subcutaneously; nadir GH 6.25 ng/mL, 19% reduction from baseline) and the invasive tumor phenotype, preoperative pasireotide (PAS) 40 mg every 4 weeks was initiated. After 2 months, partial tumor removal was performed via transsphenoidal surgery. Histological analysis revealed an immature PIT1-lineage PitNET with strong membranous expression of somatostatin receptor subtypes 2 and 5. Persistently elevated IGF-1 after surgery led to re-initiation of PAS (40 mg every 4 weeks, escalated to 60 mg), followed by the addition of pegvisomant (PEG) 10 mg/day because biochemical control could not be achieved. Combination therapy with PAS and PEG normalized IGF-1 and maintained radiological tumor stability during long-term follow-up. This case highlights that biochemical response to somatostatin receptor ligands does not necessarily correlate with receptor expression in invasive PitNETs. Pathological classification using transcription factors may help guide individualized treatment strategies. Combination therapy with PAS and PEG may represent an effective option for aggressive acromegaly caused by immature PIT1-lineage PitNETs. Learning points:
- Open Access
- 1 March 2026
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Exploring the link between atherosclerosis indicators and QT interval in type 2 diabetes: a retrospective cross-sectional analysis
Background: A prolonged QT interval is a recognized risk factor for life-threatening arrhythmias and sudden cardiac death. In patients with type 2 diabetes, identifying clinical markers associated with myocardial repolarization abnormalities is essential for risk stratification. Objectives: To investigate the association between multiple non-invasive atherosclerosis indicators and corrected QT interval prolongation in patients with type 2 diabetes. Design: Retrospective cross-sectional analysis. Methods: We evaluated 96 patients with type 2 diabetes admitted for glycemic control. The QTc interval was calculated using the Bazett (QTcB), Fridericia (QTcF), and Framingham (QTcFra) formulas. We examined the association between QTc and multiple atherosclerosis indicators, including the ankle-brachial index (ABI), cardio-ankle vascular index (CAVI), carotid intima-media thickness (IMT), and flow-mediated dilatation (FMD). Results: Among all participants, 2 women (7%) and 10 men (15%) had prolonged QTcB. In univariate analyses, FMD was negatively correlated with QTcB ( r = −0.28, p = 0.0054), whereas ABI, CAVI, mean, and maximum carotid IMT did not exhibit significant associations. In multivariable linear regression analyses, FMD was independently associated with QTcB (unstandardized coefficient β = −1.95 ms per 1% increase in FMD; 95% confidence interval −3.60 to −0.30; p = 0.021). Subgroup analysis revealed that this association was prominent specifically in the non-obese group (body mass index, <25 kg/m²). Notably, these findings remained consistent regardless of the correction formula used. Conclusion: Vascular endothelial dysfunction, as measured by FMD, is independently associated with QTc prolongation, particularly in non-obese patients with type 2 diabetes. This suggests a significant link that may help identify individuals at higher risk for life-threatening arrhythmias.
- 1 March 2026
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Open AccessExploring the link between atherosclerosis indicators and QT interval in type 2 diabetes: a retrospective cross-sectional analysis
Background: A prolonged QT interval is a recognized risk factor for life-threatening arrhythmias and sudden cardiac death. In patients with type 2 diabetes, identifying clinical markers associated with myocardial repolarization abnormalities is essential for risk stratification. Objectives: To investigate the association between multiple non-invasive atherosclerosis indicators and corrected QT interval prolongation in patients with type 2 diabetes. Design: Retrospective cross-sectional analysis. Methods: We evaluated 96 patients with type 2 diabetes admitted for glycemic control. The QTc interval was calculated using the Bazett (QTcB), Fridericia (QTcF), and Framingham (QTcFra) formulas. We examined the association between QTc and multiple atherosclerosis indicators, including the ankle-brachial index (ABI), cardio-ankle vascular index (CAVI), carotid intima-media thickness (IMT), and flow-mediated dilatation (FMD). Results: Among all participants, 2 women (7%) and 10 men (15%) had prolonged QTcB. In univariate analyses, FMD was negatively correlated with QTcB ( r = −0.28, p = 0.0054), whereas ABI, CAVI, mean, and maximum carotid IMT did not exhibit significant associations. In multivariable linear regression analyses, FMD was independently associated with QTcB (unstandardized coefficient β = −1.95 ms per 1% increase in FMD; 95% confidence interval −3.60 to −0.30; p = 0.021). Subgroup analysis revealed that this association was prominent specifically in the non-obese group (body mass index, <25 kg/m²). Notably, these findings remained consistent regardless of the correction formula used. Conclusion: Vascular endothelial dysfunction, as measured by FMD, is independently associated with QTc prolongation, particularly in non-obese patients with type 2 diabetes. This suggests a significant link that may help identify individuals at higher risk for life-threatening arrhythmias.
- Open Access
- 31 October 2025
- Published by Wiley in IJU Case Reports
- Vol. 9 (1)
Solitary Fibrous Tumor With Doege–Potter Syndrome Successfully Treated With Preoperative Transcatheter Arterial Embolization and Complete Excision; A Case Report
Introduction: Doege–Potter syndrome (DPS) is a rare paraneoplastic phenomenon of severe hypoglycemia associated with solitary fibrous tumors (SFT). We report a case of a giant pelvic SFT with DPS, which was managed with preoperative arterial embolization and complete excision. Case Presentation: This report describes the case of a 77‐year‐old patient with persistent hypoglycemia and a giant pelvic mass. He required continuous total parenteral nutrition (TPN) for severe hypoglycemia. CT showed a giant hypervascular mass (20 × 18 × 15 cm) in the pelvic space. Tumor biopsy showed SFT. To avoid intraoperative brisk bleeding, transcatheter arterial embolization (TAE) of the main feeders was performed 1 day before surgery. The tumor was completely resected via midline abdominal incision. Hypoglycemia resolved postoperatively. He was recurrence‐free for 11 months after surgery. Conclusion: The combination of preoperative TAE and surgical resection appears to be an effective therapeutic strategy for DPS‐associated SFT.
- 31 October 2025
- Published by Wiley in IJU Case Reports
- Vol. 9 (1)
Open AccessSolitary Fibrous Tumor With Doege–Potter Syndrome Successfully Treated With Preoperative Transcatheter Arterial Embolization and Complete Excision; A Case Report
Introduction: Doege–Potter syndrome (DPS) is a rare paraneoplastic phenomenon of severe hypoglycemia associated with solitary fibrous tumors (SFT). We report a case of a giant pelvic SFT with DPS, which was managed with preoperative arterial embolization and complete excision. Case Presentation: This report describes the case of a 77‐year‐old patient with persistent hypoglycemia and a giant pelvic mass. He required continuous total parenteral nutrition (TPN) for severe hypoglycemia. CT showed a giant hypervascular mass (20 × 18 × 15 cm) in the pelvic space. Tumor biopsy showed SFT. To avoid intraoperative brisk bleeding, transcatheter arterial embolization (TAE) of the main feeders was performed 1 day before surgery. The tumor was completely resected via midline abdominal incision. Hypoglycemia resolved postoperatively. He was recurrence‐free for 11 months after surgery. Conclusion: The combination of preoperative TAE and surgical resection appears to be an effective therapeutic strategy for DPS‐associated SFT.
- Open Access
- 17 March 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (4) , luaf038
Refractory Hypoglycemia Secondary to the Warburg Effect in Diffuse Large B-Cell Lymphoma
Spontaneous and refractory hypoglycemia in malignancy poses diagnostic challenges, since its exact underlying mechanisms remain unclear. A 62-year-old female patient with a 10-year type 2 diabetes mellitus history presented with abdominal pain and spontaneous hypoglycemia despite discontinuation of her diabetic treatments. An initial computed tomography (CT) scan revealed a large perinephric tumor, and a second CT, performed a week later, demonstrated significant tumor growth. On admission, she had no neuroglycopenic symptoms despite a serum glucose level of 25 mg/dL (1.39 mmol/L). She showed suppressed insulin and insulin-like growth factor (IGF)-1 levels, elevated lactate levels, a pH of 7.434 with an anion gap of 24.1, and a negative test for anti-insulin antibody. A percutaneous CT-guided tumor biopsy revealed diffuse large B-cell lymphoma. She received continuous dextrose supplementation and prednisolone to alleviate the severe hypoglycemia, but she died from the tumor burden on the sixth day of hospitalization. Postmortem serum immunoblotting revealed the absence of partially processed IGF-2 precursors. The patient's refractory hypoglycemia and hyperlactatemia were consistent with tumor-associated aerobic glycolytic lactate production, known as the Warburg effect. This case illustrates the importance of increased awareness of this underrecognized oncologic emergency in the differential diagnosis of profound spontaneous hypoglycemia in malignancy.
- 17 March 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (4) , luaf038
Open AccessRefractory Hypoglycemia Secondary to the Warburg Effect in Diffuse Large B-Cell Lymphoma
Spontaneous and refractory hypoglycemia in malignancy poses diagnostic challenges, since its exact underlying mechanisms remain unclear. A 62-year-old female patient with a 10-year type 2 diabetes mellitus history presented with abdominal pain and spontaneous hypoglycemia despite discontinuation of her diabetic treatments. An initial computed tomography (CT) scan revealed a large perinephric tumor, and a second CT, performed a week later, demonstrated significant tumor growth. On admission, she had no neuroglycopenic symptoms despite a serum glucose level of 25 mg/dL (1.39 mmol/L). She showed suppressed insulin and insulin-like growth factor (IGF)-1 levels, elevated lactate levels, a pH of 7.434 with an anion gap of 24.1, and a negative test for anti-insulin antibody. A percutaneous CT-guided tumor biopsy revealed diffuse large B-cell lymphoma. She received continuous dextrose supplementation and prednisolone to alleviate the severe hypoglycemia, but she died from the tumor burden on the sixth day of hospitalization. Postmortem serum immunoblotting revealed the absence of partially processed IGF-2 precursors. The patient's refractory hypoglycemia and hyperlactatemia were consistent with tumor-associated aerobic glycolytic lactate production, known as the Warburg effect. This case illustrates the importance of increased awareness of this underrecognized oncologic emergency in the differential diagnosis of profound spontaneous hypoglycemia in malignancy.
- Open Access
- 17 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e3063-e3069
Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
Context: In most cases of non–islet cell tumor hypoglycemia (NICTH), high molecular weight forms of insulin-like growth factor II, commonly referred to as big IGF-II, cause hypoglycemia. MicroRNA-483 (miR-483), encoded within an intron of IGF2, has been suggested to be coexpressed with IGF-II. Objective: The aim of this study is to demonstrate the utility and reliability of circulating miR-483 as a biomarker for diagnosis and therapeutic outcome of NICTH. Methods: Sera from 145 cases of suspected NICTH, and postoperative sera from 25 surgical cases of confirmed NICTH were subjected to Western blot analysis and enzyme-linked immunosorbent assay for IGF-II and quantitative polymerase chain reaction analysis for miR-483-5p and -3p. Tissue miR-483 expression levels were compared between resected solitary fibrous tumors (SFTs) and their surrounding margins from 11 surgical cases. Results: NICTH was confirmed in 100 out of 145 cases based on the detection of big IGF-II in their sera. Receiver operating characteristic curve analysis revealed that serum miR-483-5p had a better diagnostic ability for NICTH than serum IGF-II or the classical diagnostic marker the IGF-II to IGF-I ratio. Notably, serum miR-483-5p levels decreased significantly with the disappearance of big IGF-II after surgical tumor resection. Tissue miRNA-483-5p and -3p expression levels were significantly higher in resected SFT tissues than in their surgical margins. Conclusion: Circulating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.
- 17 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e3063-e3069
Open AccessPotential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
Context: In most cases of non–islet cell tumor hypoglycemia (NICTH), high molecular weight forms of insulin-like growth factor II, commonly referred to as big IGF-II, cause hypoglycemia. MicroRNA-483 (miR-483), encoded within an intron of IGF2, has been suggested to be coexpressed with IGF-II. Objective: The aim of this study is to demonstrate the utility and reliability of circulating miR-483 as a biomarker for diagnosis and therapeutic outcome of NICTH. Methods: Sera from 145 cases of suspected NICTH, and postoperative sera from 25 surgical cases of confirmed NICTH were subjected to Western blot analysis and enzyme-linked immunosorbent assay for IGF-II and quantitative polymerase chain reaction analysis for miR-483-5p and -3p. Tissue miR-483 expression levels were compared between resected solitary fibrous tumors (SFTs) and their surrounding margins from 11 surgical cases. Results: NICTH was confirmed in 100 out of 145 cases based on the detection of big IGF-II in their sera. Receiver operating characteristic curve analysis revealed that serum miR-483-5p had a better diagnostic ability for NICTH than serum IGF-II or the classical diagnostic marker the IGF-II to IGF-I ratio. Notably, serum miR-483-5p levels decreased significantly with the disappearance of big IGF-II after surgical tumor resection. Tissue miRNA-483-5p and -3p expression levels were significantly higher in resected SFT tissues than in their surgical margins. Conclusion: Circulating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.
- 25 June 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 191 (1) , 9-16
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
Objective: Widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an increase in the number of reported cases of immunotherapy-related endocrinopathies. This study aimed to analyze and compare human leukocyte antigen (HLA) signatures associated with ICI-induced type 1 diabetes (ICI-T1D) and isolated adrenocorticotropic hormone deficiency (ICI-IAD) in patients with both conditions. Methods: HLA signatures were examined for their frequencies of occurrence in 22 patients with ICI-T1D without concurrent IAD, including 16 patients from nationwide reports (ICI-T1D group) and 14 patients with ICI-IAD without concurrent T1D (ICI-IAD group). The HLA signatures were also compared for their respective frequencies in 11 patients with ICI-T1D and ICI-IAD, including eight from nationwide reports (ICI-T1D/IAD group). Results: In the ICI-T1D group, HLA-DRB1*09:01-DQB1*03:03 and DQA1*03:02, which are in linkage disequilibrium with DRB1*09:01-DQB1*03:03 and DRB1*13:02-DQB1*06:04, were susceptible to ICI-T1D, whereas DRB1*15:02-DQB1*06:01 was protective against ICI-T1D. In the ICI-IAD group, DPB1*09:01, C*12:02-B*52:01, and DRB1*15:02-DRB1*06:01, which are in strong linkage disequilibrium, were associated with susceptibility to ICI-IAD. Moreover, DRB1*15:02-DRB1*06:01 was not detected in the ICI-T1D/IAD group. Conclusions: This study revealed specific HLA signatures associated with ICI-T1D and ICI-IAD. Moreover, HLA-DRB1*15:02-DRB1*06:01, an ICI-IAD-susceptible HLA haplotype, coincides with the ICI-T1D-protective HLA haplotype, suggesting that the presence of DRB1*15:02-DRB1*06:01 may protect against the co-occurrence of T1D in patients with ICI-IAD.
- 25 June 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 191 (1) , 9-16
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
Objective: Widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an increase in the number of reported cases of immunotherapy-related endocrinopathies. This study aimed to analyze and compare human leukocyte antigen (HLA) signatures associated with ICI-induced type 1 diabetes (ICI-T1D) and isolated adrenocorticotropic hormone deficiency (ICI-IAD) in patients with both conditions. Methods: HLA signatures were examined for their frequencies of occurrence in 22 patients with ICI-T1D without concurrent IAD, including 16 patients from nationwide reports (ICI-T1D group) and 14 patients with ICI-IAD without concurrent T1D (ICI-IAD group). The HLA signatures were also compared for their respective frequencies in 11 patients with ICI-T1D and ICI-IAD, including eight from nationwide reports (ICI-T1D/IAD group). Results: In the ICI-T1D group, HLA-DRB1*09:01-DQB1*03:03 and DQA1*03:02, which are in linkage disequilibrium with DRB1*09:01-DQB1*03:03 and DRB1*13:02-DQB1*06:04, were susceptible to ICI-T1D, whereas DRB1*15:02-DQB1*06:01 was protective against ICI-T1D. In the ICI-IAD group, DPB1*09:01, C*12:02-B*52:01, and DRB1*15:02-DRB1*06:01, which are in strong linkage disequilibrium, were associated with susceptibility to ICI-IAD. Moreover, DRB1*15:02-DRB1*06:01 was not detected in the ICI-T1D/IAD group. Conclusions: This study revealed specific HLA signatures associated with ICI-T1D and ICI-IAD. Moreover, HLA-DRB1*15:02-DRB1*06:01, an ICI-IAD-susceptible HLA haplotype, coincides with the ICI-T1D-protective HLA haplotype, suggesting that the presence of DRB1*15:02-DRB1*06:01 may protect against the co-occurrence of T1D in patients with ICI-IAD.